PHARMACOECONOMIC EVALUATION OF ORPHAN DRUGS IN THE UNITED KINGDOM, FRANCE, ITALY, TURKEY AND EXPLORATION OF THE EVALUATION PROCESS OF ORPHAN DRUGS IN ALGERIA

被引：0
|
作者：
Kebaili, H. [1 ]
Djahdou, Z. [2 ]
Amrani, I [3 ]
机构：
[1] Benboulaid Univ Batna, Ager, Algeria
[2] ISPOR Chapter Algeria, Algiers 16, Algeria
[3] Benboulaid Univ Batna, Batna, Algeria
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HPR18
引用
收藏
页码：S235 / S235
页数：1
相关论文
共 34 条
  • [1] ACCESS TO ORPHAN ONCOLOGY DRUGS IN FRANCE VERSUS THE UNITED KINGDOM
    Esmail, S.
    Grosvenor, A. S.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A18 - A18
  • [2] ORPHAN DRUGS ASSESMENT IN FRANCE: ACCEPTABILITY OF THE CLINICAL DATA FOR THE ECONOMIC EVALUATION
    Bodaghi, C.
    Monnier, R.
    Bourguignon, S.
    Korchagina, D.
    [J]. VALUE IN HEALTH, 2019, 22 : S601 - S601
  • [3] ACCESSIBILITY OF ORPHAN DRUGS IN FRANCE, UNITED KINGDOM AND GERMANY: DIFFERENT APPROACHES WITH REGARD TO HTA AND PRICES
    Grandfils, N.
    Hounkanlin, H.
    Troubat, A.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A457 - A457
  • [4] A REVIEW AND EVALUATION OF SUCCESSFULLY REIMBURSED ORPHAN AND NON-ORPHAN DRUGS IN IRELAND
    Lyttle, S. J.
    Roberts, G.
    Greenwood, M.
    Mumford, A.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S275 - S275
  • [5] COMPARATIVE ANALYSIS OF HTA DECISIONS, PRICE AND REIMBURSEMENT LEVEL OF ORPHAN DRUGS IN FRANCE AND ITALY
    Korchagina, D.
    Tavella, F.
    Remuzat, C.
    Kornfeld, A.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A539 - A540
  • [6] Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007
    Orofino, Javier
    Soto, Javier
    Casado, Miguel A.
    Oyagueez, Itziar
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2010, 8 (05) : 301 - 315
  • [7] Systems for evaluation of new drugs in the United Kingdom
    Beard, K
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2001, 10 (05) : 439 - 443
  • [8] ACCESS TO ORPHAN DRUGS IN THE UNITED KINGDOM: A REVIEW OF NICE DECISIONS FROM 2017-2018
    Thorat, T.
    Sliman, R. C.
    Farinella, M.
    Vega, G.
    Jao, R.
    Kumar, J.
    Rubin, J. L.
    [J]. VALUE IN HEALTH, 2019, 22 : S862 - S862
  • [9] REIMBURSEMENT OF ORPHAN AND EXPENSIVE DRUGS IN THE NETHERLANDS: EXPLORATION OF ESSENTIAL CRITERIA IN THE DECISION MAKING PROCESS
    Tariq, L.
    Frederix, G. W.
    Roberts, R. W.
    van Bakel, P.
    Belitser, S., V
    Raaijmakers, J. A.
    Hovels, A. M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A546 - A546
  • [10] Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
    Badia, Xavier
    Chugani, Divya
    Reyes Abad, Maria
    Arias, Patricia
    Guillen-Navarro, Encarnacion
    Jarque, Isidro
    Posada, Manuel
    Vitoria, Isidro
    Luis Poved, Jose
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2019, 7 (7-8): : 363 - 372
1234